MRA(Tocilizumab)

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

Jan 1, 2005 → Oct 1, 2005

NCT ID

NCT00144573

About MRA(Tocilizumab)

MRA(Tocilizumab) is a pre-clinical stage product being developed by Chugai Pharmaceutical for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00144573. Target conditions include Rheumatoid Arthritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00380601	Phase 3	Completed	May 1, 2006	Feb 1, 2009	Rheumatoid Arthritis
NCT00144586	Phase 3	Completed	Mar 1, 2005	Jun 1, 2009	Rheumatoid Arthritis
NCT00144625	Phase 3	Completed	Feb 1, 2005	Jun 1, 2009	Polyarticular Juvenile Idiopathic Arthritis
NCT00144560	Pre-clinical	Completed	Feb 1, 2005	Aug 1, 2005	Rheumatoid Arthritis
NCT00144573	Pre-clinical	Completed	Jan 1, 2005	Oct 1, 2005	Rheumatoid Arthritis
NCT00144664	Phase 3	Completed	Nov 1, 2004	Oct 1, 2005	Systemic Juvenile Idiopathic Arthritis
NCT00144612	Phase 3	Completed	Jul 1, 2004	Jun 1, 2009	Systemic Juvenile Idiopathic Arthritis
NCT00144547	Phase 3	Completed	Apr 1, 2004	Jun 1, 2009	Rheumatoid Arthritis
NCT00144651	Phase 2	Completed	Aug 1, 2001	Jun 1, 2009	Rheumatoid Arthritis

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors

Product	Company	Stage	Hype Score
Tilmanocept	Navidea Biopharmaceuticals	Phase 1	25
Tc99m tilmanocept	Navidea Biopharmaceuticals	Phase 2	44
KPL-404 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid	Eli Lilly	Phase 3	77
LY2127399	Eli Lilly	Phase 3	77
Baricitinib + TNF Inhibitor	Eli Lilly	Approved	85
CT-P17 SC AI (adalimumab)	Celltrion	Phase 3	77
Remsima IV + Remsima SC	Celltrion	Pre-clinical	23
CT-P13 + Remicade	Celltrion	Phase 3	77
CT-P47 + EU-approved RoActemra	Celltrion	Phase 3	77
Infliximab	Celltrion	Phase 3	77
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	77
Rituximab, MTX, folic acid	Celltrion	Phase 1	33
CT-P10 + Rituxan + MabThera	Celltrion	Phase 3	77
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)	Celltrion	Phase 3	77
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 3	77
rituximab	Celltrion	Phase 1	33
CT-P17 SC + Humira SC	Celltrion	Phase 3	77
Adalimumab	Celltrion	Pre-clinical	23
Infliximab	Celltrion	Phase 3	77

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved

Pegasys® + Pegasys®Approved

ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3

R744 + Epoetin betaPhase 3

EmicizumabPhase 3